STOCKHOLM – December 21st, 2017 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence (AI), has received another U.S. patent approval for a new deep learning technology. The patent is a major upgrade of the patent “Methods and systems for automatic control of subjective image quality in imaging of objects,” which was approved in August 2017. The upgrade was filed in January 2017 and covers a new general method for supervised deep learning for automated optimization of image quality.
“This is a broad patent for important state-of the-art technology, a strong basis for future technologies, and another major milestone for ContextVision’s work in artificial intelligence for the imaging industry,” said Anita Tollstadius, CEO, ContextVision.
The patent covers a wide range of applications, including MRI, X-ray, CT and ultrasound for all kinds of images in 2D, 3D and 4D, as well as time sequences. It serves to optimize image quality throughout the image processing chain. This means using any parameter, or combination of parameters, in medical image generating systems including system parameters and post-processing parameters.
The new technology, developed within ContextVision, is a highly effective method for supervised deep learning and a sophisticated way to automate and implement deep learning to optimize image quality.
“We have continued to broaden our technology platform, and this patent demonstrates our unique expertise in deep learning and image quality technologies. The patent provides an even broader platform for the use of AI, and in particular neural networks, for automated adjustment of image quality,” said Tollstadius.
Image quality continues to be of utmost importance to healthcare professionals, and a focus for medical imaging manufacturers. The diagnostic procedure is demanding and an automated image adjustment enables image quality optimization for each patient, improving the diagnostic value of medical imaging.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, at: +46 70 337 30 26.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit https://www.contextvision.com